Skip to main content

Table 11 Results of network meta-analysis of the proportion of patients with decline in FVC≥10% predicted

From: A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials

Ambrisentan

1.52 (0.73,3.16) ⊕⊕⊕⊝moderate2

Placebo

    

2.76 (1.21,6.30) ⊕⊕⊝⊝low2,4

1.81 (1.23,2.66) ⊕⊕⊕⊕high

Nintedanib

   

2.81 (1.23,6.42) ⊕⊕⊝⊝low2,4

1.85 (1.26,2.71) ⊕⊕⊕⊕high

1.02 (0.59,1.76) ⊕⊕⊕⊝moderate4

Pirfenidone

  

3.64 (0.81,16.37) ⊕⊕⊝⊝low2,4

2.39 (0.64,8.90) ⊕⊕⊕⊝moderate2

1.32 (0.34,5.19) ⊕⊕⊝⊝low2,4

1.29 (0.33,5.08) ⊕⊕⊝⊝low2,4

Warfarin

 

6.26 (1.54,25.40) ⊕⊕⊝⊝low2,4

4.11 (1.25,13.58) ⊕⊕⊕⊕high

2.27 (0.65,7.96) ⊕⊕⊕⊝moderate4

2.23 (0.64,7.79) ⊕⊕⊕⊝moderate4

1.72 (0.29,10.16) ⊕⊕⊝⊝low2,4

Pamrevlumab

  1. Data are OR(95%Cl)
  2. 1:Certainty lowered for imprecision
  3. 2:Certainty lowered for individual study risk of bias
  4. 3:Certainty lowered two levels for imprecision
  5. 4:Certainty lowered for indirectness
  6. GRADE Working Group grades of evidence – High quality: Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality: We are very uncertain about the estimate
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us